603 related articles for article (PubMed ID: 11137832)
21. Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia.
Giral P; Bruckert E; Jacob N; Chapman MJ; Foglietti MJ; Turpin G
Atherosclerosis; 2001 Feb; 154(2):421-7. PubMed ID: 11166775
[TBL] [Abstract][Full Text] [Related]
22. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
[TBL] [Abstract][Full Text] [Related]
23. Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia.
Sasaki S; Kuwahara N; Kunitomo K; Harada S; Yamada T; Azuma A; Takeda K; Nakagawa M
Am J Cardiol; 2002 Feb; 89(4):386-9. PubMed ID: 11835916
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate.
Ooi TC; Heinonen T; Alaupovic P; Davignon J; Leiter L; Lupien PJ; Sniderman AD; Tan MH; Tremblay G; Sorisky A; Shurzinske L; Black DM
Arterioscler Thromb Vasc Biol; 1997 Sep; 17(9):1793-9. PubMed ID: 9327779
[TBL] [Abstract][Full Text] [Related]
25. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
Diabetes Atorvastin Lipid Intervention (DALI) Study Group
Diabetes Care; 2001 Aug; 24(8):1335-41. PubMed ID: 11473066
[TBL] [Abstract][Full Text] [Related]
26. Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia.
Liamis G; Kakafika A; Bairaktari E; Miltiadous G; Tsimihodimos V; Goudevenos J; Achimastos A; Elisaf M
Curr Med Res Opin; 2002; 18(3):125-8. PubMed ID: 12094821
[TBL] [Abstract][Full Text] [Related]
27. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
Hogue JC; Lamarche B; Deshaies Y; Tremblay AJ; Bergeron J; Gagné C; Couture P
Metabolism; 2008 Feb; 57(2):246-54. PubMed ID: 18191056
[TBL] [Abstract][Full Text] [Related]
28. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
Velussi M
Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
[TBL] [Abstract][Full Text] [Related]
29. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).
Malik J; Melenovsky V; Wichterle D; Haas T; Simek J; Ceska R; Hradec J
Cardiovasc Res; 2001 Nov; 52(2):290-8. PubMed ID: 11684077
[TBL] [Abstract][Full Text] [Related]
30. High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia.
Wierzbicki AS; Lumb PJ; Chik G; Crook MA
Am J Cardiol; 2000 Sep; 86(5):547-9, A9. PubMed ID: 11009276
[TBL] [Abstract][Full Text] [Related]
31. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
[TBL] [Abstract][Full Text] [Related]
32. Influence of atorvastatin versus simvastatin on fibrinogen and other hemorheological parameters in patients with severe hypercholesterolemia treated with regular low-density lipoprotein immunoadsorption apheresis.
Otto C; Geiss HC; Donner MG; Parhofer KG; Schwandt P
Ther Apher; 2000 Jun; 4(3):244-8. PubMed ID: 10910028
[TBL] [Abstract][Full Text] [Related]
33. The effects of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients with type 2 diabetes.
Tokuno A; Hirano T; Hayashi T; Mori Y; Yamamoto T; Nagashima M; Shiraishi Y; Ito Y; Adachi M
J Atheroscler Thromb; 2007 Jun; 14(3):128-32. PubMed ID: 17587764
[TBL] [Abstract][Full Text] [Related]
34. Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins.
Devroey D; Velkeniers B; Duquet W; Betz W
Acta Cardiol; 2003 Jun; 58(3):179-84. PubMed ID: 12846506
[TBL] [Abstract][Full Text] [Related]
35. Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia.
Goldammer A; Wiltschnig S; Heinz G; Jansen M; Stulnig T; Hörl WH; Derfler K
Metabolism; 2002 Aug; 51(8):976-80. PubMed ID: 12145769
[TBL] [Abstract][Full Text] [Related]
36. Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia.
Otto C; Otto B; Frost RJ; Vogeser M; Pfeiffer AF; Spranger J; Parhofer KG
Acta Diabetol; 2007 Jun; 44(2):65-8. PubMed ID: 17530469
[TBL] [Abstract][Full Text] [Related]
37. Atorvastatin versus micronized fenofibrate in the treatment of patients with mixed hyperlipoproteinemia.
Milionis HJ; Bairaktari ET; Liberopoulos EN; Elisaf MS
Am J Cardiol; 2001 Jul; 88(2):203. PubMed ID: 11463061
[No Abstract] [Full Text] [Related]
38. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.
McKenney JM; McCormick LS; Weiss S; Koren M; Kafonek S; Black DM
Am J Med; 1998 Feb; 104(2):137-43. PubMed ID: 9528731
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study.
Aguilar-Salinas CA; Gómez-Pérez FJ; Posadas-Romero C; Vázquez-Chávez C; Meaney E; Gulías-Herrero A; Guillén LE; Alvarado Vega A; Mendoza Pérez E; Eduardo Romero-Nava L; Angélica Gómez-Díaz R; Salinas-Orozco S; Moguel R; Novoa G
Atherosclerosis; 2000 Oct; 152(2):489-96. PubMed ID: 10998478
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia.
Castaño G; Mas R; Fernández L; Illnait J; Mesa M; Alvarez E; Lezcay M
Drugs Aging; 2003; 20(2):153-63. PubMed ID: 12534315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
